Form: 8-K

Current report filing

November 17, 2020

0000010795false00000107952020-11-172020-11-170000010795exch:XNYSus-gaap:CommonStockMember2020-11-172020-11-170000010795exch:XNYSus-gaap:RedeemablePreferredStockMember2020-11-172020-11-170000010795exch:XNYSbdx:Notes1.000dueDecember152022Member2020-11-172020-11-170000010795exch:XNYSbdx:Notes1.900dueDecember152026Member2020-11-172020-11-170000010795exch:XNYSbdx:Notes1.401dueMay242023Member2020-11-172020-11-170000010795exch:XNYSbdx:Notes3.020dueMay242025Member2020-11-172020-11-170000010795bdx:Notes0.174dueJune42021Memberexch:XNYS2020-11-172020-11-170000010795exch:XNYSbdx:Notes0.632dueJune42023Member2020-11-172020-11-170000010795exch:XNYSbdx:Notes1.208dueJune42026Member2020-11-172020-11-17

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) November 17, 2020
BECTON, DICKINSON AND COMPANY
(Exact Name of Registrant as Specified in Its Charter)
New Jersey
(State or Other Jurisdiction of Incorporation)
001-4802   22-0760120
(Commission File Number)   (IRS Employer Identification No.)
   
1 Becton Drive,  Franklin Lakes,
New Jersey
   07417-1880
(Address of Principal Executive Offices)   (Zip Code)
(201) 
847-6800
 (Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:


Title of Each Class Trading Symbol
Name of each exchange on
which registered
Common stock, par value $1.00 BDX New York Stock Exchange
Depositary Shares, each representing a 1/20th interest in a share of 6.00% Mandatory Convertible Preferred Stock, Series B BDXB New York Stock Exchange
1.000% Notes due December 15, 2022 BDX22A New York Stock Exchange
1.900% Notes due December 15, 2026 BDX26 New York Stock Exchange
1.401% Notes due May 24, 2023 BDX23A New York Stock Exchange
3.020% Notes due May 24, 2025 BDX25 New York Stock Exchange
0.174% Notes due June 4, 2021 BDX/21 New York Stock Exchange
0.632% Notes due June 4, 2023 BDX/23A New York Stock Exchange
1.208% Notes due June 4, 2026 BDX/26A New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐



ITEM 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On November 13, 2020, Patrick K. Kaltenbach, Executive Vice President and President, Life Sciences Segment of Becton, Dickinson and Company (“BD”), informed BD that he plans to leave BD, effective January 21, 2021, to pursue an executive leadership position based in Europe, bringing him closer to his family. As previously announced, Dave Hickey, currently President of BD’s Integrated Diagnostics Solutions business unit, will succeed Mr. Kaltenbach as President, Life Sciences Segment, effective January 1, 2021.   BD had previously announced plans to have Mr. Kaltenbach serve as BD’s Chief Technology Officer, beginning January 1, 2021.  As a result of Mr. Kaltenbach’s upcoming departure from BD, John DeFord, Executive Vice President and Chief Technology Officer, will postpone his previously announced retirement and continue to lead the company’s innovation strategy and R&D pipeline until May 28, 2021 or earlier when a successor is identified.









SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)
By: /s/ Gary DeFazio
  Gary DeFazio
  Senior Vice President and Corporate Secretary
Date: November 17, 2020